期刊文献+

大黄素逆转乳腺癌细胞多药耐药及其对ERCC1蛋白表达的影响 被引量:16

Emodin reversing multidrug resistance in breast cancer cells and its influence on expression of ERCC1
原文传递
导出
摘要 目的:探讨中药大黄素对乳腺癌MCF-7/Adr细胞株多药耐药的逆转作用,及其对细胞中ERCC1蛋白表达的影响,阐明大黄素逆转细胞耐药与ERCC1的关系。方法:采用MTT比色法进行药敏试验,蛋白质印迹法检测ERCC1蛋白的表达。结果:MCF-7/Adr对多柔比星和顺铂的耐药倍数分别为21和11倍,在加入10μg/mL大黄素后,耐药逆转倍数分别为2.86和1.79。10和20μg/mL大黄素处理MCF-7/Adr后第2、4、6、10天,ERCC1蛋白的表达呈逐渐下降趋势,在20μg/mL浓度下降低相对明显。结论:大黄素具有逆转MCF-7/Adr细胞多药耐药的作用,同时还下调了ERCC1的表达水平,并显示了一定的时间依赖性。 OBJECTIVE:To investigate the reversal effect of emodin,a traditional Chinese medicine,on multi-drug resistant breast cancer cell line MCF-7/Adr,and explore its influence on the expression of ERCC1. METHODS:MTT assay was used for drug sensitivity tests,and Western Blot was used for ERCC1 protein. RESULTS:The resistance multiples of adriamycin and cisplatin were 21 and 11 in MCF-7/Adr. The reversal multiples of drug resistance were 2.86 and 1.79,respectively,after emodin(10 μg/mL) added. MCF-7/Adr cells were treated with two concentrations (10 and 20 μg/mL) of emodin,after 2,4,6 and 10 days,the trend of ERCC1 expression was gradually downward,It was more obvious comparatively at the concentration of 20 μg/mL. CONCLUSION:Emodin can reverse the multi-drug resistance on MCF-7/Adr cells,and down-regulate the expression of ERCC1 protein in a time-dependent manner.
出处 《中华肿瘤防治杂志》 CAS 2010年第1期27-29,共3页 Chinese Journal of Cancer Prevention and Treatment
基金 深圳市科技和信息局科技计划重点项目(200601019) 深圳市卫生局重点课题项目(200628)
关键词 大黄素 乳腺肿瘤 多药耐药 基因 ERCC1 emodin breast neoplasms multidrug resistance genes ERCC1
  • 相关文献

参考文献3

二级参考文献26

  • 1陆长虹,李杰,郭伟剑,楼丽广,唐卫东,郑磊贞,章莉,沈伟.大黄素对乳腺癌多药耐药细胞株MCF-7/Adr的耐药逆转作用[J].临床肿瘤学杂志,2004,9(4):340-343. 被引量:24
  • 2潘启超,符立梧. 肺癌的药物治疗[A]. 潘启超.肿瘤药理学与化学治疗学[M].郑州: 河南医科大学出版社, 2000.541.
  • 3Kuo Y C,Meng H C,Tsai W J.Regulation of cell proliferation,inflammatory cytokine production and calcium mobilization in primary human T lymphocytes by emodin from polygonum hypolecucum Ohwi[J].Inflamm Res,2001,50(7):73-79.
  • 4Lee H Z.Effects and mechanisms of emodoin on cell death in human lung squamous cell carcinoma[J].Br J Pharmacol,2001,134(26):11-16.
  • 5孙燕.肿瘤的发生情况与防治趋势[J].中国医学论坛报,2002-28(45):14-16.
  • 6Passlick B,Kubuscho K B,Zbicki J R,et al.Isolated tumour cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer[J].Ann Thorac Surg,1999,68(5):2053-2058.
  • 7Kim N W,Piatyszek M A,Prowse K R,et al.Specific association of human telomerase activity with immortal cells and cancer[J].Science,1994,266(5):2011-2023.
  • 8Rosell R, Felip E, Paz Ares L, et al. How could pharmacogenomics help improve patient survival [J]? Lung Cancer, 2007, 57 ($2): S35-41.
  • 9Peters GJ, Van Moorsel C J, Lakerveld B, et al. Effects ofgemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or resistant human ovarian cancer cell lines[J]. Int J Oncol, 2006, 28(1): 237-44.
  • 10Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients [J ]. Clin Cancer Res, 2004, 10: 1318-5.

共引文献46

同被引文献210

引证文献16

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部